CytoDyn (CYDY) Receivables (2011 - 2025)

CytoDyn's (CYDY) quarterly Receivables came in at $2.0 million in Q2 2025, little changed on a QoQ basis from $2.0 million in Q1 2025.

CytoDyn (CYDY) Receivables (2011 - 2025) Analysis & Trends

CytoDyn (CYDY) has 4 years of Receivables data on file, last reported at $2.0 million in Q2 2025.

Quarterly Receivables changed N/A year-over-year to $2.0 million in Q2 2025, while the trailing twelve-month figure through May 2025 was $2.0 million (changed N/A YoY) and the FY2025 annual result came in at $2.0 million, changed N/A from the prior year.
Receivables held at $2.0 million in Q2 2025, from $2.0 million in the prior quarter.
In the past five years, Receivables ranged from a high of $2.0 million in Q3 2024 to a low of $41000.0 in Q3 2021.
A 3-year average of $1.4 million and a median of $2.0 million in 2024 frame the typical range for Receivables.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.93 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.06 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	1.84 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	912.74 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	215.33 Mn
10	CytoDyn	258.01 Mn	258.01 Mn	-	-

Download Data